Dose-dependent Inflammation Signatures Following Ixo-vec Administration in Non-human Primates

Adverum Biotechnologies Inc. published this content on October 25, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 10, 2025 at 10:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]